Your session is about to expire
← Back to Search
SY-5609 for Pancreatic Cancer
Study Summary
This trial will be testing a new drug, SY-5609, given alone and in combination with other drugs, to see what effect it has on treating various types of cancer.
- Solid Tumors
- Pancreatic Cancer
- Breast Cancer
- Small Cell Lung Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have advanced solid tumors that cannot be cured or controlled by standard treatments.You have a weakened immune system and are at a higher risk of getting infections.Your organs and bone marrow are working properly.
- Group 1: Group 1: Single Agent Dose Escalation
- Group 2: Group 2: SY-5609 + Fulvestrant
- Group 3: Group 4: SY-5609 + Gemcitabine + Nab-paclitaxel
- Group 4: Group 3: SY-5609 + Gemcitabine
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any prior precedents to the use of SY-5609 in clinical studies?
"At this time, 133 experiments regarding SY-5609 are in progress. 32 of these trials have reached their third phase and many are being conducted from Shanghai. However, there exists 5794 other research centres conducting studies on this therapeutic option."
Are there any opportunities to join this scientific experiment at present?
"The research project, which was first published on the 23rd of January 2020 and updated most recently on September 13th 2022, is currently in need of volunteers. This information can be found on clinicaltrials.gov."
What primary ailments does SY-5609 typically target?
"SY-5609 is a preferred treatment option for prior endocrine therapy, but clinical data indicates it may also be effective in addressing diseases of the breast and mutations to pik3ca genes."
Has the US Food and Drug Administration approved SY-5609?
"Our experts at Power assigned SY-5609 a rating of 1, as it's still in the initial phase with only limited data available regarding its safety and efficacy."
Are there numerous health care facilities in the US offering this research project?
"17 medical centres are involved in this medical trial, including University of California Los Angeles (Los Angeles), Duke University (Durham) and Banner MD Anderson Cancer Center (Gilbert). Various other sites will likewise be taking part."
How many individuals have opted to participate in this experiment?
"This trial requires 160 patients that meet the outlined criteria to partake. These individuals can be enrolled from different medical centres such as University of California Los Angeles and Duke University in Durham, North carolina."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger